Study Led by Roswell Park’s Dr. Sai Yendamuri Finds GLP-1 Receptor Agonists Improve Lung Cancer Outcomes

Lung cancer patients who take medications called GLP-1 receptor agonists — commonly prescribed for weight loss and diabetes management — fare better than those who don’t, according to research.

By
September 15, 2025
3 min

Roswell Park Comprehensive Cancer Center

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

Roswell Park Comprehensive Cancer Center

Buffalo, NY
Key Differentiators
- Thoracic Surgery
- Oncology
- Immunotherapy
#2

Columbia University Irving Medical Center

New York, NY
Key Differentiators
- Thoracic Oncology
- Immunology
- Translational Medicine
#3

MD Anderson Cancer Center

Houston, TX
Key Differentiators
- Thoracic Oncology
- Immunotherapy
- Cancer Metabolism
#4

Dana-Farber Cancer Institute

Boston, MA
Key Differentiators
- Thoracic Oncology
- Immunotherapy
- Translational Cancer Research
#5

Memorial Sloan Kettering Cancer Center

New York, NY
Key Differentiators
- Thoracic Oncology
- Immunotherapy
- Cancer Pharmacology

Study Led by Roswell Park’s Dr. Sai Yendamuri Finds GLP-1 Receptor Agonists Improve Lung Cancer Outcomes

Top Institutions in Oncology

Roswell Park Comprehensive Cancer Center

Columbia University Irving Medical Center

MD Anderson Cancer Center

Dana-Farber Cancer Institute

Memorial Sloan Kettering Cancer Center

Original Source(s)

Study Led by Roswell Park’s Dr. Sai Yendamuri Finds GLP-1 Receptor Agonists Improve Lung Cancer Outcomes

Related Content

Prognostic significance of ypN status after neoadjuvant chemoimmunotherapy in resectable NSCLC: a systematic review and meta-analysis

Gut microbiome functional pathways outperform taxonomic profiles in predicting immune checkpoint inhibitor response in non-small cell lung cancer: an interpretable machine learning approach with SHAP

FOXA2 in cancer: from fundamental biology to clinical translation